<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>HFpEF • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="HFpEF • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/HFpEF/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/HFpEF/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="hfpef" tabindex="-1">HFpEF</h1>
<ul>
<li>related: <a href="/wiki/notes/Cardiology/">Cardiology</a></li>
<li>tags: #note</li>
</ul>
<hr>
<h2 id="pathophysiology" tabindex="-1">Pathophysiology</h2>
<h3 id="normal" tabindex="-1">normal</h3>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20211107132848.png" alt=""></p>
<ul>
<li>Passive: LV relaxation</li>
<li>Active: Atrial kick</li>
</ul>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20211107132901.png" alt=""></p>
<ul>
<li>As we age, LV stiffens up</li>
<li>Passive filling goes down</li>
<li>we rely more on atrial kick</li>
<li>LA pressure is normal however</li>
</ul>
<h3 id="pseudonormal-lv-filling" tabindex="-1">Pseudonormal LV filling</h3>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20211107132926.png" alt=""></p>
<ul>
<li>Mild HFpEF</li>
<li>LAP very high: high gradient</li>
<li>atrial kick not as high</li>
<li>More passive filling due to high gradient</li>
</ul>
<h3 id="resistant-lv-filling" tabindex="-1">Resistant LV filling</h3>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20211107132911.png" alt=""></p>
<ul>
<li>LAP very very high</li>
<li>LV can't accommodate</li>
</ul>
<hr>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20210218121702.png" alt="">
<img src="https://photos.thisispiggy.com/file/wikiFiles/20210218122554.png" alt="">
<img src="https://photos.thisispiggy.com/file/wikiFiles/20210218123555.png" alt="">
<img src="https://photos.thisispiggy.com/file/wikiFiles/20210218123708.png" alt=""></p>
<ul>
<li>strict BP maybe not help</li>
</ul>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20210218124156.png" alt="">
<img src="https://photos.thisispiggy.com/file/wikiFiles/20210218124454.png" alt=""></p>
<h2 id="uworld" tabindex="-1">Uworld</h2>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220806092001.png" alt="">
<img src="https://photos.thisispiggy.com/file/wikiFiles/20220807085946.png" alt="">
This patient has <strong>heart failure with preserved ejection fraction</strong> (HFpEF), with signs and symptoms of volume overload, <strong>normal</strong> left ventricular ejection fraction (LVEF) (<strong>&gt;50%</strong>), and left ventricular hypertrophy.</p>
<p>In comparison with heart failure with <em>reduced</em> ejection fraction (HFrEF), HFpEF has overall demonstrated less response to neurohormonal antagonists (eg, angiotensin system blockers, beta blockers); however, <strong>aldosterone antagonists</strong> (eg, spironolactone) have been shown to reduce hospitalizations and possibly improve survival.  Optimal management of HFpEF involves the following:</p>
<ul>
<li><strong>Afterload reduction</strong> (ie, blood pressure &lt;130/80 mm Hg).  Aldosterone antagonists are first-line therapy.</li>
<li>Treatment of <strong>volume overload</strong> with diuretics</li>
<li>Treatment of <strong>exacerbating conditions</strong> (eg, rate control of atrial fibrillation, coronary revascularization)</li>
</ul>
<p>In addition, <strong>exercise training</strong> in a <strong>cardiac rehabilitation program</strong> has been shown to improve functional capacity and overall quality of life in patients with HFpEF.</p>
<h2 id="medications" tabindex="-1">Medications</h2>
<p>Several studies show a clear benefit of <strong>aldosterone receptor antagonists</strong> (eg, spironolactone) and <strong>sodium-glucose cotransporter 2 (SGLT2) inhibitors</strong> (eg, dapagliflozin) for HFpEF.  These agents lower systemic afterload, improve diastolic function, attenuate cardiac hypertrophy, and help achieve euvolemia through their diuretic effects.</p>
<p>Beta blockers improve survival in patients with HFrEF, but they have not shown similar benefit in patients with HFpEF.  In the management of HFpEF they are useful for reducing the ischemic burden of coronary artery disease and for rate control of atrial fibrillation, but in the absence of these indications they provide minimal clinical benefit.</p>
<p>This patient's blood pressure is currently under control and long-acting nitrates have not shown any particular benefit in patients with HFpEF.  In fact, these drugs are associated with decreased activity levels and occasional hypotension in such patients and should be avoided.  Suitable options for blood pressure control in patients with HFpEF include aldosterone antagonists, angiotensin system blockers, dihydropyridine calcium channel blockers, and beta blockers (eg, carvedilol).</p>
<p>Phosphodiesterase-5 inhibitors (eg, sildenafil) are indicated for pulmonary arterial hypertension (ie, group 1 pulmonary hypertension), but they have demonstrated no benefit for pulmonary hypertension resulting from left-sided heart disease (ie, group 2 pulmonary hypertension).</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        <nav class="toc" >
        <ul><li><a href="#pathophysiology">Pathophysiology</a><ul><li><a href="#normal">normal</a></li><li><a href="#pseudonormal-lv-filling">Pseudonormal LV filling</a></li><li><a href="#resistant-lv-filling">Resistant LV filling</a></li></ul></li><li><a href="#uworld">Uworld</a></li><li><a href="#medications">Medications</a></li></ul>
      </nav>
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Heart Failure/" class="peer">Heart Failure</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="heart-failure" tabindex="-1">heart failure</h1>
<ul>
<li>related: <a href="/wiki/notes/Cardiology/">Cardiology</a>, <a href="/wiki/notes/HFpEF/">HFpEF</a></li>
<li>tags: #cardiology</li>
</ul>
<h2 id="causes" tabindex="-1">Causes</h2>
<p>Drug induced cardiomyopathy includes <a href="/wiki/notes/trastuzumab%20and%20anthracycline/">trastuzumab and anthracycline</a>.
Structural causes can include <a href="/wiki/notes/Acute%20mitral%20regurgitation%20can%20cause%20acute%20heart%20failure/">acute mitral regurgitation from either ruptured chordae tendinae or papillary muscle</a>.</p>
<ul>
<li><a href="/wiki/notes/monitoring%20heart%20function%20in%20chemotherapy/">monitoring heart function in chemotherapy</a></li>
</ul>
<h3 id="hfref-causes" tabindex="-1">HFrEF Causes</h3>
<ul>
<li>ischemic: angina, risks, wall motion, LHC, EKG changes, positive stress te</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
